- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04872608
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study With Letrozole, Palbociclib and Onapristone ER
Study Overview
Status
Intervention / Treatment
Study Type
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Komal Jhaveri, MD
- Phone Number: 646-888-5145
- Email: jhaverik@mskcc.org
Study Contact Backup
- Name: Joshua Drago, MD
- Phone Number: 646-888-6971
Study Locations
-
-
New York
-
Harrison, New York, United States, 10604
- Memorial Sloan Kettering Westchester (All Protocol Activities)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Histologically confirmed ER+, PR+, HER2- metastatic or unresectable breast cancer
- PR positivity is defined as ≥1% expression by immunohistochemistry (IHC) on fresh or archival tumor tissue
- Tissue samples obtained, stained, and interpreted outside of MSKCC will be accepted
- Those patients who do not have adequate/accessible archival tissue available and for whom biopsy is not a significant risk procedure may be required to consent to pretreatment biopsy
Completed at least 6 months (+/- 4 weeks) of first-line letrozole/palbociclib without radiological progression or unresolved toxicity
°Patients who underwent dose reduction of palbociclib to 100mg daily or 75mg daily will be eligible if:
- The dose reduction was implemented ≥4 weeks prior to enrollment
- Patients have demonstrated resolution of all acute toxic effects of prior therapy to NCI CTCAE (Version 5.0) Grade ≤ 1
ctDNA-positive, defined as:
°Presence of a tumor-derived somatic mutation in the peripheral blood using the MSK-ACCESS assay after 6 months of letrozole/palbociclib (+/- 4 weeks); at least one mutation should have avariant allele fraction of ≥ 0.5%
- Completed MSK IMPACT testing from primary or metastatic tissue
- Radiologically evaluable or measurable disease per RECIST Version 1.1
- Age ≥ 18 years
- Pre-menopausal patients are eligible as long as they are on LHRH agonist for at least four weeks prior to starting trial therapy and commit to continue LHRH agonist for as long as patient is receiving trial therapy or medical contraindications arise.
- Eastern Cooperative Oncology Group Performance Status (ECOG) of 1 or Karnofsky Performance Status (KPS) of ≥ 70%
Women of child-bearing potential:
- Must have a negative pregnancy test within 14 days prior to commencement of study treatment
- Agreement to remain abstinent (refrain from heterosexual intercourse) or use nonhormonal contraceptive methods with a failure rate of <1% per year during the treatment period and for 120 days after the last dose and agreement to refrain from donating eggs during this same period
- Note: for women with therapy-induced amenorrhea, baseline measurements of FSH and/or estradiol are needed to ensure menopausal status.
Adequate hematologic and organ function demonstrated within 14 days prior to initiation of study treatment, defined by the following:
- Absolute neutrophil count ≥ 1.2K/ µL
- Hemoglobin ≥ 9 g/dL
- Platelet count ≥ 100,000/ µL
- Total bilirubin ≤ 1.5 x ULN
- Serum albumin ≥ 2.5 g/dL
- AST and ALT ≤ 2.5 x ULN
- Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation
INR < 1.5 x ULN and aPTT < 1.5 x ULN
°For patients requiring anticoagulation therapy with warfarin, a stable INR between 2-3 is required. If anticoagulation is required for a prosthetic heart valve, then stable INR between 2.5-3.5 is permitted.
- At least 4 weeks post-op from any major surgical procedure
- Patients with asymptomatic brain metastases which have been treated with surgery or radiation and demonstrate stability for ≥ 3 months will be allowed
- Able to swallow tablets whole, without crushing
Exclusion Criteria:
- Radiologic disease progression while on treatment with letrozole and palbociclib in the first line prior to enrollment
- History of another invasive malignancy (other than non-melanoma skin cancer or curatively treated in situ carcinoma) with evidence of disease within the past 3 years
- Any psychological, familial, sociological or geographic condition that would potentially hinder compliance with the study protocol
- Known untreated or symptomatic brain metastasis
- Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95mmHg) despite medical treatment. Patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment.
- Clinically significant heart disease as evidenced by myocardial infarction or arterial thrombotic event within the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction measurement of < 50% at baseline
- Screening ECG with rate-corrected (using Friderica's correction) QT interval (QTcF) of >480 msec or a history of cardiac arrythmias
- Refractory nausea and vomiting, requirement for parenteral hydration and/or nutrition, drainage gastrostomy tube, malabsorption, external biliary shunt, or significant small bowel resection that would preclude adequate study drug absorption
- Is pregnant or breastfeeding, and/or expecting to conceive within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
- Current use of estrogen or progesterone products including intrauterine and implantable contraceptive devices.
- Anticipated or ongoing administration of anti-cancer therapies other than those administered in this study
- Active Hepatitis B (HBsAg positive or hepatitis B virus DNA≥1×10^3 copy/ml) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
- Use of any prescription medication during the prior 28 days of first onapristone dosing that the investigator judges is likely to interfere with onapristone activity; specifically, strong inhibitors or inducers, or sensitive substrates of cytochrome P450 CYP3A4.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Letrozole, Palbociclib, and Onapristone ER
This study has two stages: a dose-finding stage and a dose expansion stage.
Stage 1 of the study will utilize a standard 3+3 dose de-escalation design with a total of three dose levels of onapristone ER, 30mg PO BID, 40mg PO BID, and 50mg PO BID given on a 28-day cycle.
Onapristone ER will be given in addition to letrozole 2.5mg QD and each patient's pre-enrollment dose of palbociclib.
|
Letrozole will be given daily on days 1-28.
Palbociclib will be given daily on days 1-21 and held on days 22-28, as per standard FDA-approved dosing guidelines.
Onapristone will be given daily on days 1-28.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
recommended phase 2 dose (RP2D) of onapristone ER
Time Frame: 1 year
|
The RP2D/MTD will be defined as the dose level at which a dose limiting toxicity (DLT) occurs in at most 1 out of 6 patients in that dose cohort.
|
1 year
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protein Kinase Inhibitors
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Letrozole
- Palbociclib
- Onapristone
Other Study ID Numbers
- 21-194
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisDaiichi SankyoRecruitingAdvanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast CarcinomaFrance
Clinical Trials on Letrozole
-
Helsinki University Central HospitalFoundation for Paediatric Research, FinlandCompletedConstitutional Delay of Growth and PubertyFinland
-
Rovi Pharmaceuticals LaboratoriesRecruiting
-
Institut du Cancer de Montpellier - Val d'AurelleNovartisCompleted
-
University of Alabama at BirminghamGenentech, Inc.; Breast Cancer Research FoundationCompletedBreast Cancer | Breast Neoplasm | Cancer of the BreastUnited States
-
Fudan UniversityRecruitingEndometrial CancerChina
-
Wyeth is now a wholly owned subsidiary of PfizerPfizerCompletedBreast Neoplasms
-
IVI MadridActive, not recruitingLuteinised Follicular CystSpain
-
Assiut UniversityRecruitingInfertility, FemaleEgypt
-
Novartis PharmaceuticalsCompletedBreast NeoplasmUnited States, Germany, Spain, United Kingdom, France, Austria, Russian Federation, Italy, Canada, Belgium
-
Cairo UniversityAhmed Elgazzar HospitalCompleted